PALO ALTO, California, Feb 3 (LifeSiteNews) – Novartis, a world leader in healthcare with core businesses in pharmaceuticals, consumer health, generics, eye-care, and animal health is involved with the grisly trade in aborted baby parts. LifeSite News has obtained an order form for baby parts from Life Dynamics which notes that Systemix, a wholly owned subsidiary of Novartis, is requesting “thymus,”“liver,”“mesentery,”“leg/arm bone,” and “spleen” from aborted babies beyond 18 weeks gestation.
The order form, called a protocol, is dated September 1990 and requests that the baby parts are to “be removed and prepared” (for shipping on ice) “within a maximum of ten minutes after circulation has stopped.” A note at the top of the protocol indicates that Systemix is the baby parts’ marketer’s “biggest account.” Systemix, in Palo Alto California is involved in both stem cell research and gene therapy experimentation for Novartis. Headquartered in Basel, Switzerland, Novartis employs about 82,000 people and operates in over 140 countries around the world. In 1998, the Group (including Agribusiness) achieved sales of over $27 billion (CDN).
To express your concerns to Systemix or Novartis:
[email protected]
https://www.info.novartis.com/contact/